Her previous roles include a stint as the head of development for oncology cell therapies at Takeda. She also led the North American Innovation Center and R&D Digital Accelerator at Sanofi and held a leadership role in Lilly’s oncology business unit. Bit.bio’s differentiated approach Corzo’s decision to join bit.bio was rooted in the company’s pioneering…
Synthetica Bio lates to tap generative AI to spur drug discovery innovation
Interest in generative AI has skyrocketed in 2023. While the generative AI market is already substantial, worth $10 billion in 2022 according to Grand View Research, it is set to balloon by a compound annual growth rate (CAGR) of 35.6% from 2023 to 2030. It’s no wonder that a slew of companies — including Exscientia,…
Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
Neurodegenerative disease research is witnessing significant advances. To that end, Hong Kong-headquartered Aprinoia Therapeutics is embracing a ‘precision neuroscience’ approach to neurodegeneration diagnostics. The company’s lead program, APN-1607, represents a new generation of advanced tau positron emission tomography (PET) tracers, which play a crucial role in effective and efficient diagnosis of patients suffering from neurodegenerative…